2014-2017 Mardin Devlet Hastanesi - Dahiliye Uzmanı

2017-2020 Ümraniye Eğitim Araştırma Hastanesi - Dahiliye Uzmanı

2020-2023 Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi - Tıbbi Onkoloji Yan Dal Asistanı

2023-2025 Osmaniye Devlet Hastanesi - Onkoloji Uzmanı

2025-Halen İstanbul Onkoloji Hastanesi - Onkoloji Uzmanı

Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer Yardımcı Araştırmacı

A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemtrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Yardımcı Araştırmacı

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer Yardımcı Araştırmacı

A Phase III, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer (LUMINANCE) Yardımcı Araştırmacı

A Phase III, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2) Yardımcı Araştırmacı

A Randomized, Double-Blind, Phase III Placebo Controlled Trial of Pemrolizumab (MK3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination Advanced/Metastatic Esophageal Carcinoma Yardımcı Araştırmacı

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study

of Encorafenib+Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5FU)/Folinic Acid (FA) / Irinotecan (FOLFIRI) /Cetuximab with a Safety Lead-in of Encorafenib+Binimetinib+Cetuximab in Patients with BRAF V600E Yardımcı Araştırmacı

ESR1 Mutasyonlu, Lokal olarak İlerlemiş veya Metastatik ER+/HER2− Meme Kanseri Olan Menopoz Öncesi ve Sonrası Kadın ve Erkeklerin Tedavisinde, Fulvestrant ve Abemasiklib Kombinasyonuna Kıyasla Lasofoksifen ve Abemasiklib Kombinasyonunun Etkililiğinin ve Güvenliliğinin Karşılaştırıldığı, Açık Etiketli, Randomize, Çok Merkezli bir Çalışma, SMX 22-002 (Elaine 3) Yardımcı Araştırmacı

A Randomized, Double Blind, Placebo – Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU) Yardımcı Araştırmacı

A Phase 3 randomized, double-blind study to compare the efficacy and safety of pembrolizumab (MK3475) in combination with lenvatinib versus pembrolizumab and placebo as first-line treatment for locally advanced or metastatic urothelial carcinoma in cisplatin-ineligible participants whose tumors express PD-L1 and participants ineligible for any platinum-containing chemotherapy regardless of PD-L1 expression (LEAP-011) Yardımcı Araştırmacı

A Multicenter, Randomized, Double-blind, Phase III Study of BAT1706 versus EU-Avastin® plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer Yardımcı Araştırmacı

A Randomized, Phase 3 Trial with Anti-PD Monoclonal Antibody Pembrolizumab (MK3475) Versus Placebo for Patients with Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS) Yardımcı Araştırmacı

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE826) Yardımcı Araştırmacı

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects who have Relapsed After, or are Refractory to Standard Therapy Yardımcı Araştırmacı

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK3475/ SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-Line Treatment of Subjects with Extensive Stage Small Lung Cancer Yardımcı Araştırmacı

A Phase 4, Randomized, Open-Label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-Hormonal Therapy (NAH) in Patients with Bone Dominant Metastatic Castration-Resistant Prostate Cancer (mCRPC) Progressing On/After One Line of NAH Yardımcı Araştırmacı

A Global, Randomized, Phase 3, Open-Label Study of Regn2810 (Anti-PD-1 Antibody) Versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer Yardımcı Araştırmacı

Randomized, Double-Blind, Parallel Group, Multi-Center, Phase III Equivalence Study (SAMSON-II) comparing the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of HD204 with Avastin® in Patients with Metastatic or Recurrent, Non-Squamous, Non-Small Cell Lung Cancer Yardımcı Araştırmacı

A Phase III, Multicenter, Randomized, Open-Label Study comparing Atezolizumab (Anti-PD-L1 Antibody) in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients with Operable Triple-Negative Breast Cancer Yardımcı Araştırmacı

A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First-Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma Yardımcı Araştırmacı

A Phase III, Randomized, Double-Blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-Line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Yardımcı Araştırmacı

A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer Yardımcı Araştırmacı

849-021

A Randomized Study of Two Dosing Regimens of Adagrasib in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation Baş Araştıcı